Welcome to our dedicated page for REPLIGEN SEC filings (Ticker: RGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REPLIGEN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REPLIGEN's regulatory disclosures and financial reporting.
Repligen Corporation (RGEN) is registering shares of its common stock to be issued as part of a cash-and-stock acquisition of BioLife Solutions, Inc. Repligen will acquire BioLife through a two-step merger, after which BioLife will become a wholly owned subsidiary and its stock will be delisted from Nasdaq.
For each BioLife share, holders will receive $11.25 in cash plus 0.1442 shares of Repligen common stock, with cash paid instead of fractional Repligen shares. A special virtual meeting of BioLife stockholders on October 5, 2026 will vote on adopting the merger agreement, an advisory compensation proposal, and a meeting adjournment proposal.
BioLife’s board (with one director recused) unanimously recommends voting in favor of all three proposals. Completion of the transaction depends on stockholder approval, antitrust and other regulatory clearances, listing of the new Repligen shares on Nasdaq, and the absence of specified adverse events. BioLife stockholders who meet strict Delaware procedures may seek appraisal instead of the stated merger consideration.
REPLIGEN CORP (RGEN) has a notice of proposed sale of common stock filed under Rule 144 for the account of Olivier Loeillot. The notice covers 3,035 shares of common stock, related to restricted stock vesting on September 3, 2026, to be sold through Fidelity Brokerage Services LLC.
In the prior three months, Loeillot reported a separate sale of 5,426 shares of common stock for an aggregate consideration of $976,680.00.
Repligen Corporation (RGEN) has filed an amended Form S-4 to register shares of its common stock to be issued to stockholders of BioLife Solutions in connection with a two-step merger that will make BioLife a wholly owned subsidiary of Repligen.
Each BioLife share will be converted into the right to receive $11.25 in cash plus 0.1442 shares of Repligen common stock, with cash paid instead of fractional Repligen shares. The exchange ratio is fixed, so the share portion’s value will fluctuate with Repligen’s stock price. A special virtual BioLife stockholder meeting is scheduled for October 5, 2026, with a record date of September 3, 2026, to vote on the merger and related proposals.
Closing is subject to BioLife stockholder approval, antitrust and other regulatory clearances, Nasdaq listing of the new Repligen shares, accuracy of representations and covenants, and absence of specified material adverse effects. BioLife stockholders have appraisal rights under Delaware law if they follow strict procedures instead of taking the merger consideration.
REPLIGEN CORP (RGEN) reported insider equity activity by Chief Accounting Officer Violetta Hughes. On March 5, 2026, she received a grant of 2,466 restricted stock units, each representing a contingent right to one share of common stock that vests in equal annual installments over four years. On September 1, 2026, 277 shares of common stock were withheld by Repligen to satisfy tax withholding obligations arising from the release of restricted stock units, at a reference value of $170.02 per share.
Repligen Corporation (RGEN) has filed a Form S-4 to register shares of its common stock to be issued as part of the acquisition of BioLife Solutions, Inc. through a two-step merger. BioLife will first merge into a Repligen subsidiary and ultimately become a wholly owned Repligen subsidiary.
For each BioLife share (with specified exceptions), holders will receive $11.25 in cash plus 0.1442 shares of Repligen common stock, with cash paid instead of fractional Repligen shares. The stock portion is based on a fixed exchange ratio, so its value will vary with RGEN’s market price.
The BioLife board (with one director recused) unanimously recommends that BioLife stockholders vote for the merger and related proposals at a special virtual meeting. The deal requires approval by a majority of outstanding BioLife shares, expiration of HSR and other antitrust or foreign investment reviews, Nasdaq listing of the new Repligen shares, and other closing conditions. BioLife stockholders have appraisal rights under Delaware law. Centerview Partners delivered a fairness opinion on the consideration and is to receive about $25 million in fees, largely contingent on closing. If certain competing-transaction or recommendation-change events occur, BioLife may owe Repligen a $59 million termination fee.
REPLIGEN CORP (RGEN) reported Form 4 activity by Chief Executive Officer Olivier Loeillot involving an option exercise and share sale. On August 20, 2026, he exercised a stock option to acquire 5,426 shares of common stock at an exercise price of $141.79 per share, and on the same date sold 5,426 shares of common stock at $180.00 per share. The option exercise reduced the reported option position by 5,426 shares, leaving 10,852 stock options outstanding after the transaction at the same exercise price and with an expiration date of September 3, 2034. The filing states that these sales were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025, and that an additional 5,426 shares will vest on each of September 3, 2026 and September 3, 2027.
Repligen Corp (RGEN) received a Rule 144 notice that Olivier Loeillot intends to sell up to 5,426 shares of Repligen common stock through Fidelity Brokerage Services LLC. The shares are to be sold on or after 08/20/2026 on NASDAQ in connection with a stock option exercise.
T. Rowe Price Associates, Inc. filed an amended ownership report for Repligen Corp. (common stock), stating beneficial ownership of 1,751,887 shares of common stock, representing 3.1% of the class as of 06/30/2026. The firm reports sole voting power over 1,744,549 shares and sole dispositive power over 1,751,887 shares, with no shared voting or dispositive power. The filer notes that this reflects ownership of 5 percent or less of the class and expressly denies that the filing should be construed as an admission of beneficial ownership beyond what is required to be reported.
Vanguard Capital Management reports beneficial ownership of 2,825,579 shares of Repligen Corp common stock, representing 5% of the class. Vanguard has sole voting power over 414,408 shares and sole dispositive power over all 2,825,579 shares, with no shared voting or dispositive power.
The filing explains that these securities are held across Vanguard Capital Management LLC and several affiliated entities and business divisions, including various Vanguard funds and managed accounts. Vanguard and its registered investment companies and other accounts have the right to receive dividends and sale proceeds, but no other single person has an interest in more than 5% of the securities reported.
Repligen Corporation reported Q2 2026 revenue of $204.1 million, up 11.9% from Q2 2025, and first-half revenue of $398.4 million, up 13.3%. Product growth was broad-based across filtration, chromatography, process analytics and proteins. Gross margin improved to 53.9% from 51.0%, driven by favorable product mix and better leverage on indirect labor and overhead.
Net income fell to $5.0 million in Q2 and $13.3 million year-to-date, reflecting a higher effective tax rate and a $13.7 million loss on the sale of Polymem S.A.S. Repligen ended June with $606.8 million in cash and equivalents plus $203.7 million in U.S. Treasury bills and generated $61.1 million of operating cash flow in the first half. The company is restructuring its manufacturing footprint, incurring $4.2 million of charges year-to-date and targeting completion by 2027. Subsequent to quarter-end, it agreed to acquire BioLife Solutions for approximately $1.5 billion, with BioLife stockholders to receive $11.25 in cash plus 0.1442 Repligen shares per BioLife share, subject to customary approvals and a planned closing in the fourth quarter of 2026.